Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you for your honesty here. Phase 2/3 on deck. Funding news will be forthcoming.
No gap...ah nice to be king.
The wording from PR said they have funds to "prepare" for phase 2/3 AD, Parkinson and Retts syndrome in 2017. Dr Missling has said there would be a partnering for a large placebo controlled phase 2/3 Alzheimer's trial. I for one am waiting for the Biogen results.
I also believe you guys are on to something with the idea that A-273 sets to promote healing and regeneration of brain cells over time. A-273 is not just another drug that blows out the pipes so to speak.
I find the "THERAPEUTIC RESPONSE UNEXPECTED" on slide 30 impressive. I counted some 16 patients all with remarkable change of life anecdotal evidence. These folks are improving and getting on with a fuller life.
SGX942 study is IV 2x week after radiation treatment requiring clinician to dose. B-OM oral rinse will be a prescription that a patient could dose at home saving money.
Good post. Yes it all falls back on the data and not the price gyrations. I don't pay attention to the gap yappers.
I agree. But being it's a Saturday it won't matter market wise.
Thank You Boston. That makes perfect sense.
I'm not sure if there is a webcast. I was wondering if we could hear Dr Misslings oral presentation.
Where can I find a link to tomorrows webcast? TIA
I'll pass.
AIR001 now in 3 phase 2 trials. Positive outcome could result in a lucrative buyout next year. Current trials are already funded.
Anecdotal evidence: Pianist Pauline Stevens has regained the ability to play the piano after being placed on the experimental Anavex 2-73 drug trial at Caulfield Hospital.
Award-winning artist Valerie Lynch has also rediscovered the ability to paint after beginning the medication, stunning her doctors, family and friends.
https://www.google.com/#q=melbourne+au+anavex+273+piano+player
Arch Therapeutics to Present at 9th Annual LD Micro Main Event on December 7, 2016.
https://finance.yahoo.com/news/arch-therapeutics-present-9th-annual-230342924.html
News of expected partnership will go a long ways to stop the shorts.
Update at 41 weeks looks quite promising. Maybe a momentous December after all.<wink>
I think we got the news 11/22.. "At 41 weeks, Alzheimer’s patients taking a daily oral dose of ANAVEX 2-73 in the exploratory, not yet dose optimized Phase 2a clinical trial, showed a stabilization of cognitive and functional measures. This data of stabilization is promising since Alzheimer’s disease is a progressive disease where current therapeutics are only able to temporarily slow the worsening of dementia symptoms and not stop the disease from progressing."
Also this: George Perry, PhD, Dean and Professor at the University of Texas at San Antonio and Editor-in Chief of the Journal of Alzheimer’s Disease, commented, “Although this is an open label study with 32 patients, I have never seen mild-to-moderate Alzheimer’s patients maintain near baseline cognitive and activities of daily living function and positive correlation with all other measures over a 41-week trial period in any prior study with an approved or experimental drug. It is quite plausible that complex CNS diseases like Alzheimer’s may require a comprehensive approach, including restoration of cellular homeostasis.”
Yes thanks, got the PM also and yes great observation and thanks for posting.
Extension design was to provide continued access to A-273. Wording of A-273 as add-on therapy to SOC dropped.
Thanks for the reply. I do find it intriguing though not to see any mention of Donepezil combination at 41 weeks.
"Initially planned for 26 weeks, PART B was extended to 52 weeks as a result of requests from patients and caregivers". Are all patients taking A-273 in the extended trial? No mention of Donepezel in 41 week update.
No worries as current share price is not even close to present or future value. . 2017 the year of ctix.
Keep looking.
He loves to stand corrected. Well he's been corrected. lol
Much more going on here then Prurisol, could see $4 before March.
Thank you. The next update will be another huge vote of confidence for B not only for UP but also OM as a anti-inflamatory. Leo and company getting the business done..
News will move ctix stock. When can we expect the next UP update? TIA
Exactly. A non-toxic pill will bring in a hefty upfront payment. The best part about going into P phase2b is we know the stuff works good. This trial will show just how good.
Question: Which of the three drugs has garnered the most attention? "we are fortunate that all three of our drug candidates have appealed to partnering opportunities". "It's more prudent for us to take into consideration for what a partner wants and make that happen". "During past few months we've engaged in more business development and had more high level meetings then anytime in company's history". "we maintain ongoing discussions with multiple potential corporate partners and also continue to develop new relationships to that point we've signed CDA's with some of the largest pharmas and biotech's.
Sounds like big pharma may be advising behind the scenes.
No word was mentioned regarding the material transfer agreements with university laboratories. Also no update regarding MTA with the large pharmaceutical. I know we were updated at one time that the large pharma had requested more compound. Sure would be nice to know how that collaboration is going.
Wrong board??eom
Great price momentum. Election spawned new buying for ctix the little pharma that could. Buyers are seeing the great opportunity longs have watched mature. Great pipeline, multiple trials, positive results are bringing in new and returning buyers, slow at first but then lots of fun when the flood gates open. Hopefully it's enough to spur uplisting. Lot's of stuff happening. Positive P2b interim data will be more icing on the cake.
Evidence has been provided proving in fact cellceutix is a real company with a real drug pipeline in real multiple ongoing FDA trials. Many invested here have been here for years and have seen many just like you come along announcing scam and like them you too will fade away just like the all politicians after election.
You called this company a scam so why stick around or even give a rats behind about 5yrs. Except you know this company is not a scam and with every trial approval the potential for longs to see hyper price appreciation is now only weeks or a few months away. Ctix trials will have the last word not basement pundits.
Cempra antibiotic seen as toxic and yet gets FDA pass. Brilacidin should pass FDA panel with flying colors when it gets through phase3.
https://www.washingtonpost.com/politics/fda-panel-narrowly-backs-cempra-antibiotic/2016/11/04/9ea9f8f0-a2d4-11e6-8864-6f892cad0865_story.html
Yes and if it wasn't for "them" shareholders wouldn't have been screwed over by a lying hit piece and then the company spending money defending itself in a lawsuit cooked up by a so called law firm.
We already had very positive results at lower dose. Surely a pill that can alleviate or even go as far as cure plaque psoriasis has the makings of a big deal. I would bet Dr Bertolino made this known to big pharma and they going to be closely watching p2 escalated dosage trial closely.
Yes agree a lot riding on 52 week data.
9TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) DECEMBER 8-10, 2016.
Oral Session, Saturday Dec10 8.45 a.m OC59 - 9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study
in Mild-to-Moderate Alzheimer’s Disease Patients.
Probably this: "Mast Therapeutics Announces Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001" 10/16
Delivery device agreement very positive for AIR001. Phase2 update promised 4th quarter.
Patients take their set dosing for a full 12 weeks. Patient enrollment is staggered.